Is VXF a Good ETF to Buy?
Vanguard’s Extended Market ETF (VXF) is a broad fund made…
Sell
16
CYTK Quote, Financials, Valuation and Earnings
Last price:
$43.24
Seasonality move
:
3.26%
Day range:
$42.47 - $44.08
52-week range:
$40.53 - $75.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
265.41x
P/B ratio:
61.87x
Volume:
1.2M
Avg. volume:
1.8M
1-year change:
-33.95%
Market cap:
$5.2B
Revenue:
$18.5M
EPS (TTM):
-$5.26
Analysts' Opinion
-
Consensus RatingCytokinetics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $79.10, Cytokinetics has an estimated upside of 80.26% from its current price of $43.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing 100% downside risk from its current price of $43.88.
Fair Value
-
According to the consensus of 13 analysts, Cytokinetics has 80.26% upside to fair value with a price target of $79.10 per share.
CYTK vs. S&P 500
-
Over the past 5 trading days, Cytokinetics has underperformed the S&P 500 by -4.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cytokinetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cytokinetics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Cytokinetics reported revenues of $16.9M.
Earnings Growth
-
Cytokinetics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cytokinetics reported earnings per share of -$1.26.
Enterprise value:
4.8B
EV / Invested capital:
9.16x
Price / LTM sales:
265.41x
EV / EBIT:
--
EV / Revenue:
258.58x
PEG ratio (5yr expected):
-0.66x
EV / Free cash flow:
-11.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$320.9M
Return On Assets:
-49.18%
Net Income Margin (TTM):
-3191.11%
Return On Equity:
--
Return On Invested Capital:
-123.83%
Operating Margin:
-821.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $94.6M | $7.5M | $18.5M | $1.7M | $16.9M | |
| Gross Profit | -$146.2M | -$322.6M | -$320.9M | -$83.3M | -$76.7M | |
| Operating Income | -$324.2M | -$496.2M | -$536.2M | -$127.4M | -$139M | |
| EBITDA | -$332M | -$456.7M | -$493.5M | -$113.5M | -$125M | |
| Diluted EPS | -$4.25 | -$5.45 | -$5.26 | -$1.38 | -$1.26 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $474.2M | $535.7M | $795.2M | $628.1M | $1.1B | |
| Total Assets | $533.8M | $841.3M | $1B | $824.3M | $1.4B | |
| Current Liabilities | $31.2M | $71.9M | $84.6M | $102.7M | $179.7M | |
| Total Liabilities | $420.4M | $597.5M | $1.1B | $1.2B | $1.5B | |
| Total Equity | $113.4M | $243.9M | -$107.9M | -$386.3M | -$135.4M | |
| Total Debt | $135.7M | $142.8M | $610.6M | $617.5M | $657.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$299.5M | -$414.3M | -$395.9M | -$74M | -$65.6M | |
| Cash From Investing | -$262.1M | $239.3M | -$553.1M | -$81.4M | $110.9M | |
| Cash From Financing | $516.2M | $221.3M | $930.6M | $168.8M | $2.4M | |
| Free Cash Flow | -$310.9M | -$415.7M | -$399.8M | -$74.1M | -$66.9M | |
CYTK
Sector
Market Cap
$5.2B
$38.4M
Price % of 52-Week High
57.96%
44.83%
Dividend Yield
0%
0%
Shareholder Yield
-12.89%
-0.67%
1-Year Price Total Return
-33.95%
-40.84%
Beta (5-Year)
0.949
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$45.93
200-day SMA
Sell
Level
$52.35
Bollinger Bands (100)
Sell
Level
46.06 - 53.4
Chaikin Money Flow
Buy
Level
21.7M
20-day SMA
Sell
Level
$45.63
Relative Strength Index (RSI14)
Sell
Level
43.25
ADX Line
Sell
Level
15.69
Williams %R
Neutral
Level
-71.65
50-day SMA
Sell
Level
$47.00
MACD (12, 26)
Sell
Level
-0.71
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
138M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9043)
Sell
CA Score
(Annual)
Level (-5.8685)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.0807)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Stock Forecast FAQ
In the current month, CYTK has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CYTK average analyst price target in the past 3 months is $79.10.
-
Where Will Cytokinetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cytokinetics share price will rise to $79.10 per share over the next 12 months.
-
What Do Analysts Say About Cytokinetics?
Analysts are divided on their view about Cytokinetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cytokinetics is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is Cytokinetics's Price Target?
The price target for Cytokinetics over the next 1-year time period is forecast to be $79.10 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CYTK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cytokinetics is a Buy. 10 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CYTK?
You can purchase shares of Cytokinetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cytokinetics shares.
-
What Is The Cytokinetics Share Price Today?
Cytokinetics was last trading at $43.24 per share. This represents the most recent stock quote for Cytokinetics. Yesterday, Cytokinetics closed at $43.88 per share.
-
How To Buy Cytokinetics Stock Online?
In order to purchase Cytokinetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is PM Stock Up So Much?
Shares of cigarette giant Philip Morris (NYSE:PM) have advanced considerably…
Is Nvidia Stock Still Too Expensive or a Smart Buy?
The $2.8 trillion chip juggernaut NVIDIA Corporation (NASDAQ:NVDA) announced Q4…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
53
SITM alert for Mar 6
SiTime [SITM] is down 2.22% over the past day.
Buy
71
ASTS alert for Mar 6
AST SpaceMobile [ASTS] is down 4.73% over the past day.
Sell
20
MRNA alert for Mar 6
Moderna [MRNA] is down 2.56% over the past day.
